Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer

NCT07581184 is registered in ClinicalTrials.gov with Aktis Oncology, Inc. as lead sponsor.

NCT NCT07581184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Aktis Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 17, 2026
Completion date
June 30, 2032
Enrollment
138 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b7h3, castration resistant metastatic prostate cancer, mcrpc, mcrpc (metastatic castration-resistant prostate cancer), prostate cancer